Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lytix Biopharma AS ( (DE:6BG) ) has provided an announcement.
Lytix Biopharma has secured shareholder approval for a series of corporate actions, including a subsequent offering of up to NOK 30 million directed at eligible existing shareholders, the conversion from a private to a public limited liability company with a name change to Lytix Biopharma ASA, and an authorization for the board to increase share capital. The extraordinary general meeting also approved amendments to the company’s articles of association, elected Darlene Deptula-Hicks as an additional board member until 2027, and set the subscription period for the new share offering from 27 January to 10 February 2026, steps that collectively strengthen Lytix’s capital base, governance and public-market profile as it advances its oncology pipeline.
More about Lytix Biopharma AS
Lytix Biopharma is an Oslo-based clinical-stage biotech company developing cancer immunotherapies derived from host-defense peptides. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule intended to boost anti-cancer immunity, supported by a broader pipeline targeting multiple tumor types both as monotherapy and in combination regimens.
YTD Price Performance: -9.31%
Average Trading Volume: 87,676
Current Market Cap: NOK672.8M
For an in-depth examination of 6BG stock, go to TipRanks’ Overview page.